MedWatch

Genmab: Janssen dispute cost DKK 146m in H1

Genmab's ongoing arbitration case with partner Janssen Pharmaceuticals has resulted in the latter withholding DKK 146m in royalty payments during the first half of 2021, the Danish biotech group informs.

Photo: Tuala Hjarnø / Genmab / PR

Even though Genmab's superseller, Darzalex, brought in USD 2.8bn in the first half of 2021 against USD 1.8bn from the same period last year – thereby playing a role in driving the recent guidance upgrade – the Danish biotech group is still able to note some less fortunate news for the period.

The company's second-quarter interim report shows that Genmab's royalty payments from Janssen Pharmaceuticals, which sells Darzalex on behalf of Genmab, only increased by 43 percent despite a 52 percent growth in sales during the same period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs